<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="157955">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01758393</url>
  </required_header>
  <id_info>
    <org_study_id>PUMCH-GC-IgG4RD</org_study_id>
    <nct_id>NCT01758393</nct_id>
  </id_info>
  <brief_title>Glucocorticoids in Patients With IgG4-RD</brief_title>
  <official_title>A Randomized Trial of Glucocorticoids in Patients With IgG4-Related Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <authority>China: National Natural Science Foundation</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, open-label, single-center clinical trial to compare the efficacy and
      safety profile for medium-dose versus high dose glucocorticoid in patients with IgG4-related
      Disease. Patients will be followed for three months to measure the primary outcome and
      secondary outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Complete Response</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Complete Response(CR) is defined as resolution of clinical manifestations, biochemical tests (C-reactive Proteins and IgG or IgG4 levels), and imaging studies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease Response</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Disease Response is measured by IgG4-RD Responder Index(IgG4-RD RI) and defined as:
Improvement of &gt; 2 points in the IgG4-RD RI over baseline
No disease flares, as assessed by the IgG4-RD RI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Effect</measure>
    <time_frame>3 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Treatment-related adverse effect, including glucocorticoid-induced diabetes mellitus and infections.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>IgG4-related Disease</condition>
  <arm_group>
    <arm_group_label>Medium Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are treated with prednisone or equivlent at doseage of 0.5-0.6 mg/kg/d (max 40mg daily) for 3 weeks, then tapering gradually to 15mg/d in 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are treated with prednisone or equivlent at doseage of 0.8-1.0 mg/kg/d (max 60mg daily) for 3 weeks, then tapering gradually to 15mg/d in 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <arm_group_label>Medium Dose</arm_group_label>
    <arm_group_label>High Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females

          -  Age 18-70 years old with informed consent

          -  Patients with IgG4-RD:

               1. swelling, sclerosing and inflammatory involvement of one or more organ,
                  including sclerosing pancreatitis, sclerosing cholangitis, inflammatory
                  pseudotumors, retroperitoneal or mediastinal fibrosis, interstitial nephritis,
                  hypophysitis, sclerosing dacryoadenitis, sialadenitis, inflammatory aortic
                  aneurysm, lymphadenopathy, or other inflammatory conditions;

               2. elevated serum IgG4 (&gt;1.35 g/L)

               3. histopathologic features of fibrosis and/or lymphocytic and polyclonal plasma
                  cell infiltration (and IgG4+ plasma cells on immunohistology when performed);

               4. exclusion of other diseases.

        Exclusion Criteria:

          -  Previously or currently received glucocorticoid and(or) immunomodulator

          -  Pregnancy or lactating

          -  Concurrent severe and/or uncontrolled and/or unstable diseases

          -  Patient with malignancy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wen Zhang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deptment of Rheumatology, Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Fengchun Zhang</last_name>
    <role>Study Chair</role>
    <affiliation>Deptment of Rheumatology, Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hua Chen, MD</last_name>
    <phone>+86-10-69158797</phone>
    <email>chenhua@pumch.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Deptment of Rheumatology, Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wen Zhang, MD</last_name>
      <phone>+86-10-69158795</phone>
      <email>zhangwen91@sina.com</email>
    </contact>
    <contact_backup>
      <last_name>Hua Chen, MD</last_name>
      <phone>+86-10-69158797</phone>
      <email>chenhua@pumch.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <lastchanged_date>December 24, 2012</lastchanged_date>
  <firstreceived_date>December 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking Union Medical College Hospital</investigator_affiliation>
    <investigator_full_name>Wen Zhang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>IgG4-related disease</keyword>
  <keyword>IgG4-RD</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glucocorticoids</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
